Numbers and rates of incident tuberculosis, limited to first anti-TNF drug. (Follow-up censored at date of starting second anti-TNF drug)
| Number of patients ever received the drug | DMARD (n=3232) | All anti-TNF (n=10 712) | ETA (n=3913) | INF (n=3295) | ADA (n=3504) |
|---|---|---|---|---|---|
| On drug* | |||||
| Person-years | 7345 | 23 286 | 10 111 | 7459 | 5716 |
| Cases of TB | 24 | 4 | 11 | 9 | |
| Rate/100 000 person-years (95% CI) | 103 (66 to 153) | 40 (11 to 101) | 147 (74 to 264) | 157 (72 to 299) | |
| IRR, adjusted for age, gender and entry year (95% CI) | Referent | 3.7 (1.1 to 12.7) | 4.4 (1.3 to 15.2) | ||
| Most recent drug* | |||||
| Person-years | 7345 | 27 624 | 11 926 | 8963 | 6735 |
| Cases of TB | 33 | 6 | 12 | 15 | |
| Rate/100 000 personyears (95% CI) | 119 (82 to 168) | 50 (18 to 110) | 134 (69 to 234) | 223 (125 to 367) | |
| IRR, adjusted for age, gender and entry year (95% CI) | Referent | 2.7 (0.9 to 7.8) | 4.4 (1.6 to 12.1) | ||
↵* The two models of risk attribution are illustrated in fig 1.
ADA, adalimumab; DMARDs, disease modifying antirheumatic drugs; ETA, etanercept; INF, infliximab; IRR, incidence rate ratio; TB, tuberculosis; TNF, tumour necrosis factor.